Skip to main content

Advertisement

SpringerLink
Log in

Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes

  • Original article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

In order to identify new compounds which label platelets without affecting their function, three classes of metal chelating agents have been compared with oxine for their efficiency of indium-113m platelet labelling and for their short- and long-term effects on platelet function. The 3-hydroxypyridinones (both 2-ones and 4-ones) and 3-hydroxypyranones are bidentate chelators of trivalent metal ions that are neutrally charged in the metal-complexed form and hence gain access to cells readily. The hydroxypyranone ethylmaltol has been compared with the 3-hydroxypyridin-4-one CP94 and to its structurally related lipophilic analogue CP25 as well as with the 3-hydroxypyridin-2-one, CP02. The platelet labelling efficiencies with these ligands were between 75% and 95% of that obtained with oxine, following a 12-min incubation in saline. The optimal concentration for the hydroxypyridin-2-ones and hydroxypyridin-4-ones was approximately 10 μM compared with 100 μM for the hydroxypyranone ethylmaltol and 60 μM for oxine. Oxine and tropolone were found to produce significant inhibition of platelet aggregation to collagen in short-term experiments (10 min) or in longer term (18 and 42 h) ex vivo platelet cultures respectively. By contrast, ethylmaltol had no such inhibitory effects at either time interval. The relatively hydrophilic hydroxypyridin-4-one CP94 showed no inhibitory effects on collagen-induced aggregation in short-term studies, unlike the more lipid-soluble derivative CP25. These results suggest that ethylmaltol and related pyranones may have advantages over oxine and tropolone as indium platelet labelling agents where it is important not to damage platelets by the labelling process itself.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thakur ML, Welch MJ, Joist JH, et al. Indium-111 labelled platelets: studies on preparation and evaluation of in vivo and in vitro functions. Thromb Res 1976; 9: 345–357.

    Google Scholar 

  2. Davis HH, Siegel BA, Joist JH, et al. Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by indium-111-labelled autologous platelets. Lancet 1978; I: 1185–1187.

    Google Scholar 

  3. Hawker RJ, Hawker LM, Wilkinson AR. Use of indium II I/oxine to label human platelets. Lancet 1978; II: 483.

    Google Scholar 

  4. Joist JH, Baker RK, Thakur ML, et al. Indium-111-labelled human platelets: uptake and loss of label and in vitro function of labelled platelets. J Lab Clin Med 1978; 92: 829–836.

    Google Scholar 

  5. Heaton WA, Davis HH, Welch MJ, et al. Indium-111: a new radionuclide label for studying human platelet kinetics. Br J Haematol 1979; 42: 613–622.

    Google Scholar 

  6. Hawker RJ, Hawker LM Wilkinson AR. Indium ( 111In)-labelled human platelets: optimal method. Clin Sci 1980; 58: 243–248.

    Google Scholar 

  7. Thakur ML, Walsh L, Malech HL, et al. Indium-111-labelled human platelets: improved method, efficacy, and evaluation. J Nucl Med 1981; 22: 381–385.

    Google Scholar 

  8. Dewanjee MK, Rao SA, Didisheim P. Indium-111 tropolone, a new high-affinity platelet label: preparation and evaluation of labelling parameters. J Nucl Med 1981; 22: 981–987.

    Google Scholar 

  9. Dewanjee MK, Rao SA, Rosemark JA. Indium-111 tropolone, a new tracer for platelet labelling. Radiology 1982; 145: 149–153.

    Google Scholar 

  10. Vallabhajosula S, Machac J, Goldsmith SJ, et al. Indium-111 platelet kinetics in normal human subjects: tropolone versus oxine methods. J Nucl Med 1986; 27: 1669–1674.

    Google Scholar 

  11. I.C.S.H. Panel. Recommended method for indium-111 platelet survival studies. J Nucl Med 1988; 29: 564–566.

    Google Scholar 

  12. Danpure HJ, Osman S, Peters AM. Labelling autologous platelets with 111In tropolonate for platelet kinetic studies: limitations imposed by thrombocytopenia. Eur J Haematol 1990;45:223–230.

    Google Scholar 

  13. Thakur ML, McKenney SL, Park CH. Simplified and efficient labelling of human platelets in plasma using indium-111–2-mercaptopyridine-N-oxide: preparation and evaluation. J Nucl Med 1985; 26: 510–517.

    Google Scholar 

  14. Hill-Zobel RL, Gannon S, McCandless B, et al. Effects of chelates and incubation media on platelet labelling with indium-111. J Nucl Med 1987; 28: 223–228.

    Google Scholar 

  15. Segal AW, Deteix P, Garcia R, et al. Indium-111 labeling of leukocytes: a detrimental effect on neutrophil and lymphocyte function and an improved method of cell labeling. J Nucl Med 1978;19:1238–1244.

    Google Scholar 

  16. Chisholm PM, Danpure HG, Healey G, et al. Cell damage resulting from the labelling of rat lymphocytes and HeLa S3 cells with In-111 oxine. J Nucl Med 1979; 20: 1308–1311.

    Google Scholar 

  17. Berge RIM, Natarajan AT, Hardeman MR, et al. Labelling with indium-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med 1983; 24: 615–620.

    Google Scholar 

  18. Kassis Al, Adelstein SJ. Chemotoxicity of indium-111 oxine in mammalian cells. J Nucl Med 1985; 26: 187–190.

    Google Scholar 

  19. Signore A, Sensi M, Pozzilli C, et al. The effect of indium oxine and indium tropolone (not radiolabelled) on the function of isolated human lymphocytes. Br J Radiol 1985; 58: 929.

    Google Scholar 

  20. Signore A, Sensi M, Pozzilli C, et al. Effect of unlabelled indium oxine and indium tropolone on the function of isolated human lymphocytes. J Nucl Med 1985; 26: 612–615.

    Google Scholar 

  21. Balaban EP, Simon TR, Frenkel EP. Toxicity of indium-111 on the radiolabelled lymphocyte. J Nucl Med 1987; 28: 229–233.

    Google Scholar 

  22. Gunter KP, Lukens JN, Clanton JA, et al. Neutrophil labelling with indium-111: tropolone vs. oxine. Radiology 1983; 149: 563–566.

    Google Scholar 

  23. Spicer KM, Lowe L, Gordon L. Tropolonate vs oxine 111-indium platelet labelling: comparison of efficacy, ultrastructure and function [abstract]. J Nucl Med 1984; 25: 99.

    Google Scholar 

  24. Vallabhajosula S, Machac J, Lipszyc H, et al. 111-In platelet survival kinetics: tropolone vs oxine method [abstract]. J Nucl Med 1985; 26:48.

    Google Scholar 

  25. Porter JB, Abeysinghe RD, Hoyes KP, et al. Indium labelling of blood cells using hydroxypyridinone and hydroxypyrone chelators. Br J Haematol 1990; 74: 10.

    Google Scholar 

  26. Hider RC, Hall AD. Clinically useful chelators of tripositive elements. New York: Elsevier; 1991: 41–173.

    Google Scholar 

  27. Hider RC, Huehns ER, Porter JB. Metal complexes. UK Patent 91061374, 1991.

  28. Hider RC, Kontoghiorges G, Silver J. Pharmaceutical compositions. UK Patent GB 2136807A, 1984.

  29. Hider RC, Kontoghiorges G, Silver J, et al. Pharmaceutical active hydroxypyridones. UK Patent GB 2146989, 1984.

  30. Hider RC, Kontoghiorges G, Silver J. Pharmaceutical compositions. UK Patent GB 2118176A, 1982.

  31. Hider RC, Kontoghiorges G, Silver J, et al. 1-Hydroxypyrid-2-ones. UK Patent GB2146990A, 1984.

  32. Matsuba CA, Nelson WO, Rettig SJ, et al. Neutral water-soluble indium complexes of 3-hydroxy-4-pyrones and 3-hydroxy4-pyridones. Inorg Chem 1988; 27: 3935–3939.

    Google Scholar 

  33. Gralla EJ, Stebbins RB, Coleman GL, et al. Toxicity studies with ethyl maltol. Toxicol Appl Pharmacol 1969; 15: 604–613.

    Google Scholar 

  34. Gyparaki M, Porter JB, Hirani S, et al. In vivo evaluation of hydroxypyridone iron chelators in a mouse model. Acta Haematol (Basel) 1987; 78: 217–221.

    Google Scholar 

  35. Porter JB, Morgan J, Hoyes KP, et al. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 1990; 76: 2389–2396.

    Google Scholar 

  36. Porter JB, Hoyes KP, Abeysinghe RD, et al. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelatorsin overloaded and nonoverloaded mice. Blood 1991;78:2727–2734.

    Google Scholar 

  37. Porter J, Singh S, Epimolou O, et al. Oral efficacy and metabolism of 1,2 diethyl-3-hydroxypyridin-4-one in thalassaemia major. Blood 1991; 78: 207.

    Google Scholar 

  38. Streater M, Taylor PD, Hider RC, et al. Novel 3-hydroxy2(1H)-pyridinones. Synthesis, iron(III)-chelating properties and biological activity. J Med Chem 1990; 33: 1749–1755.

    Google Scholar 

  39. Dobbin PS, Hider RC, Hall AD, et al. Synthesis, physicochemical properties and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J Med Chem 1993; 36: 2448–2458.

    Google Scholar 

  40. Sampson CB. Textbook of radiopharmacy — theory and practice. New York: Gordon and Breach Science Publishers, 1990.

    Google Scholar 

  41. McClelland DBL. Handbook of transfusion medicine. Her Majesty's Stationery Office, 1989.

  42. Giannessi D. Optimization and comparison of indium oxine and tropolone techniques for platelet radiolabelling. Thromb Haemost 1991; 65: 1147.

    Google Scholar 

  43. Porter JB, Huehns ER, Hider RC. The development of iron chelating drugs. Baillieres Clin Haematol 1989; 2: 257–292.

    Google Scholar 

  44. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993;85:393–400.

    Google Scholar 

  45. Subramanian G. Radiopharmaceuticals. New York: The Society of Nuclear Medicine, 1975.

    Google Scholar 

  46. Danpure HJ, Osman S. Cell labelling and cell damage with indium-III acetylacetone — an alternative to indium 111 oxine. Br J Radiol 1981; 54: 597–601.

    Google Scholar 

  47. Thakur ML, Segal AW, Louis L, et al. Indium-111-labelled cellular blood components: mechanism of labelling and intracellular location in human neutrophils. J Nucl Med 1977; 18: 1020–1024.

    Google Scholar 

  48. Mathias C, Welch M. Labelling mechanism and localization of indium-111 in human platelets. J Nucl Med 1979; 20: 659.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Haematology, University College Medical School, London

    R. D. Abeysinghe & J. B. Porter

  2. Department of Pharmacy, Kings College, London

    B. L. Ellis & R. C. Hider

Authors
  1. R. D. Abeysinghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. L. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. C. Hider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. B. Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abeysinghe, R.D., Ellis, B.L., Hider, R.C. et al. Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes. Eur J Nucl Med 21, 1141–1147 (1994). https://doi.org/10.1007/BF00181071

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00181071

Key words

Search

Navigation